Avantor, Inc. (NYSE:AVTR) CAO Steven W. Eck Sells 3,525 Shares

Avantor, Inc. (NYSE:AVTR) CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Avantor Trading Down 0.4 %

NYSE:AVTR opened at $25.55 on Friday. The stock has a market cap of $17.35 billion, a price-to-earnings ratio of 65.50, a PEG ratio of 2.64 and a beta of 1.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. Avantor, Inc. has a 1 year low of $16.63 and a 1 year high of $28.00. The business has a fifty day moving average of $23.86 and a 200-day moving average of $24.20.

Avantor (NYSE:AVTR) last announced its earnings results on Friday, July 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. Avantor had a net margin of 5.28% and a return on equity of 12.40%. The firm had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.70 billion. Equities analysts predict that Avantor, Inc. will post 1.01 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. New York Life Investment Management LLC increased its position in shares of Avantor by 13.7% during the 4th quarter. New York Life Investment Management LLC now owns 10,979 shares of the company’s stock valued at $251,000 after purchasing an additional 1,321 shares during the period. First Trust Direct Indexing L.P. bought a new position in Avantor during the fourth quarter valued at about $224,000. Amalgamated Bank grew its holdings in Avantor by 3.9% during the fourth quarter. Amalgamated Bank now owns 68,344 shares of the company’s stock worth $1,560,000 after acquiring an additional 2,546 shares during the period. Metis Global Partners LLC raised its position in Avantor by 4.2% in the fourth quarter. Metis Global Partners LLC now owns 25,255 shares of the company’s stock worth $577,000 after acquiring an additional 1,027 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Avantor by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,528,759 shares of the company’s stock valued at $57,732,000 after acquiring an additional 75,450 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Evercore ISI lowered their price target on Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Stifel Nicolaus boosted their target price on shares of Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 target price on shares of Avantor in a report on Monday, July 29th. Morgan Stanley lifted their price target on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Finally, Barclays increased their price objective on shares of Avantor from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.40.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.